Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
5(100.0%)
5Total
Phase 4(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07690397Phase 4Active Not Recruiting

Dorzolamide/Brimonidine/Timolol Impact on Ocular Surface, Glaucoma Progression & Chatbot Follow-up: GLAUCO-TECH

Role: lead

NCT06367452Phase 4Completed

Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of Magaldrate

Role: lead

NCT06162442Unknown

Management of the Ocular Surface With Preservative-Free Lubricants in Patients With Dry Eye

Role: lead

NCT04573907Phase 4Completed

Bioequivalence Study of Levothyroxine Sodium Tablets 100 mcg

Role: lead

NCT03914534Phase 4Completed

Bioequivalence Study of Sodium Divalproate Tablets 500 mg

Role: lead

NCT03634371Phase 4Unknown

Bioequivalence Study of Levothyroxine Sodium Tablets 150 mcg

Role: lead

All 6 trials loaded